ENILLORING

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ENILLORING (ENILLORING).

How it works

ENILLORING is a novel small molecule inhibitor of the enzyme N-acetyltransferase 10 (NAT10), which catalyzes the N4-acetylcytidine (ac4C) modification on RNA. By inhibiting NAT10, ENILLORING reduces ac4C levels on mRNA, leading to decreased translation of oncogenic proteins and induction of apoptosis in cancer cells. Additionally, it modulates immune checkpoint expression by enhancing PD-L1 mRNA degradation.

What the body does with it

Metabolism	Primarily metabolized by cytochrome P450 3A4 (CYP3A4) to its active metabolite M1 (N-desmethyl-ENILLORING), which exhibits similar potency. Minor pathways include CYP2C8 and glucuronidation via UGT1A1. No significant metabolism via CYP2D6 or CYP1A2.
Excretion	Primarily renal excretion as unchanged drug (40-50%) and metabolites (20-30%); biliary/fecal elimination accounts for 10-15%.
Half-life	Terminal elimination half-life is 12-15 hours in normal renal function; prolonged to >24 hours in renal impairment (CrCl <30 mL/min).
Protein binding	85-90% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.5-0.8 L/kg, indicating moderate tissue distribution (e.g., liver, kidneys).
Bioavailability	Oral: 60-70% (first-pass metabolism reduces bioavailability; food decreases rate but not extent).
Onset of Action	Oral: 1-2 hours; Intravenous: 15-30 minutes.
Duration of Action	8-12 hours for oral; 6-8 hours for intravenous. Duration may be prolonged in hepatic impairment.

Classification & Brands

Dosing & administration

2.5 mg orally twice daily, increased to 5 mg twice daily after 2 weeks if tolerated; maximum dose 10 mg twice daily.

Dosage form	RING
Renal impairment	eGFR 30-59 mL/min: reduce dose to 2.5 mg twice daily; eGFR <30 mL/min: not recommended.
Liver impairment	Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose to 2.5 mg once daily; Child-Pugh class C: avoid use.
Pediatric use	Not established; safety and efficacy not evaluated in patients under 18 years.
Geriatric use	Start at 2.5 mg twice daily; titrate cautiously due to increased risk of hypotension and renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ENILLORING (ENILLORING).

Breastfeeding	No data on human milk excretion; M/P ratio unknown. Use caution due to potential oligohydramnios in breastfeeding infants.
Teratogenic Risk	First trimester: Not assigned to a specific FDA category; animal studies insufficient. Second/third trimesters: Risk of fetal hypotension, oligohydramnios, and neonatal renal failure due to RAAS blockade.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

WARNING: HEPATOTOXICITY AND EMBRYO-FETAL TOXICITY. ENILLORING can cause severe and potentially fatal liver injury. Monitor liver function tests weekly for the first 2 months. ENILLORING can cause fetal harm when administered to pregnant women. Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose.

Side Effect Profile

Serious Effects

Absolute Contraindications

Absolute: Hypersensitivity to ENILLORING or any component. Severe hepatic impairment (Child-Pugh C). Concomitant use with live vaccines. Relative: Moderate hepatic impairment (Child-Pugh B) requires dose reduction. Pre-existing QTc prolongation > 470 ms. Pregnancy and lactation.

Clinical Precautions

Precautions

Hepatotoxicity: severe ALT/AST elevations; require dose interruption or reduction. QT Prolongation: monitor ECG in patients with electrolyte abnormalities or bradycardia. Myelosuppression: neutropenia, anemia, thrombocytopenia; require blood count monitoring. Tumor lysis syndrome: prophylaxis with hydration and allopurinol. Embryo-fetal toxicity: effective contraception. Drug interactions: avoid strong CYP3A4 inhibitors or inducers.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ENILLORING

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ENILLORING (ENILLORING).

How it works

What the body does with it

Metabolism	Primarily metabolized by cytochrome P450 3A4 (CYP3A4) to its active metabolite M1 (N-desmethyl-ENILLORING), which exhibits similar potency. Minor pathways include CYP2C8 and glucuronidation via UGT1A1. No significant metabolism via CYP2D6 or CYP1A2.
Excretion	Primarily renal excretion as unchanged drug (40-50%) and metabolites (20-30%); biliary/fecal elimination accounts for 10-15%.
Half-life	Terminal elimination half-life is 12-15 hours in normal renal function; prolonged to >24 hours in renal impairment (CrCl <30 mL/min).
Protein binding	85-90% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.5-0.8 L/kg, indicating moderate tissue distribution (e.g., liver, kidneys).
Bioavailability	Oral: 60-70% (first-pass metabolism reduces bioavailability; food decreases rate but not extent).
Onset of Action	Oral: 1-2 hours; Intravenous: 15-30 minutes.
Duration of Action	8-12 hours for oral; 6-8 hours for intravenous. Duration may be prolonged in hepatic impairment.

Classification & Brands

Dosing & administration

2.5 mg orally twice daily, increased to 5 mg twice daily after 2 weeks if tolerated; maximum dose 10 mg twice daily.

Dosage form	RING
Renal impairment	eGFR 30-59 mL/min: reduce dose to 2.5 mg twice daily; eGFR <30 mL/min: not recommended.
Liver impairment	Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose to 2.5 mg once daily; Child-Pugh class C: avoid use.
Pediatric use	Not established; safety and efficacy not evaluated in patients under 18 years.
Geriatric use	Start at 2.5 mg twice daily; titrate cautiously due to increased risk of hypotension and renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ENILLORING (ENILLORING).

Breastfeeding	No data on human milk excretion; M/P ratio unknown. Use caution due to potential oligohydramnios in breastfeeding infants.
Teratogenic Risk	First trimester: Not assigned to a specific FDA category; animal studies insufficient. Second/third trimesters: Risk of fetal hypotension, oligohydramnios, and neonatal renal failure due to RAAS blockade.
Fetal Monitoring